Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
A1cGlycated hemoglobin (hemoglobin A1c)
AACEAmerican Association of Clinical Endocrinology
ABCDAdiposity-based chronic disease
ACCAmerican College of Cardiology
ACOFPAmerican College of Osteopathic Family Physicians
ADAAmerican Diabetes Association
AEAdverse event
AESIAdverse event of special interest
AFAtrial fibrillation
AGAAmerican Gastroenterological Association
AHAAmerican Heart Association
AHFSAmerican Hospital Formulary Service
AHIApnea-hypopnea index
ALTAlanine aminotransferase
ANCOVAAnalysis of covariance
AOMAnti-obesity medication
APIActive pharmaceutical ingredient
ASCVDAtherosclerotic cardiovascular disease
ASMBSAmerican Society for Metabolic and Bariatric Surgery
ASTAspartate aminotransferase
AUCArea under the concentration-time curve
AWPAverage wholesale price
BLBaseline
BMIBody mass index
BRFSSBehavioral Risk Factor Surveillance System
BWMPBehavioral weight management program
CADCoronary artery disease
CBOCongressional Budget Office
CDCCenters for Disease Control and Prevention
CDMOContract development and manufacturing organization
CIConfidence interval
CKDChronic kidney disease
CmaxMaximum plasma concentration
CMCChemistry, manufacturing, and controls
CMSCenters for Medicare & Medicaid Services
COPDChronic obstructive pulmonary disease
CTCCommon Terminology Criteria
CVCardiovascular
CVDCardiovascular disease
CYP3A4Cytochrome P450 3A4
DLRTDose Level Review Team
DPP-4Dipeptidyl peptidase 4
DSEDiabetes Support and Education
ECOEuropean Congress on Obesity
eGFREstimated glomerular filtration rate
EOIEnd of intervention
EQ-5DEuroQol 5-dimension questionnaire
ESKDEnd-stage kidney disease
ETDEstimated treatment difference
evLYEqual value of life year
FDAU.S. Food and Drug Administration
FPGFasting plasma glucose
GDPGross domestic product
GIGastrointestinal
GIPGlucose-dependent insulinotropic polypeptide
GLP-1Glucagon-like peptide-1
GLP-1 RAGlucagon-like peptide-1 receptor agonist
HBPBHealth benefit price benchmark
HbA1cGlycated hemoglobin (hemoglobin A1c)
HDL-CHigh-density lipoprotein cholesterol
HFHeart failure
HFpEFHeart failure with preserved ejection fraction
HFrEFHeart failure with reduced ejection fraction
HRHazard ratio
HRQoLHealth-related quality of life
hsCRPHigh-sensitivity C-reactive protein
ICERInstitute for Clinical and Economic Review
IFSOInternational Federation for the Surgery of Obesity and Metabolic Disorders
ILIIntensive lifestyle intervention
iNHBIncremental net health benefit
IRRIncidence rate ratio
ITTIntention to treat
IWQOL-Lite-CTImpact of Weight on Quality of Life-Lite Clinical Trials Version
IWRSInteractive Web Response System
KFFKaiser Family Foundation
LDL-CLow-density lipoprotein cholesterol
LISLow-income subsidy
LSLeast squares
MACEMajor adverse cardiovascular events
MADMultiple ascending dose
MASHMetabolic dysfunction-associated steatohepatitis
MASLDMetabolic dysfunction-associated steatotic liver disease
MBEModel-based estimate
MBSMetabolic and bariatric surgery
MCSMental component summary
MEN2Multiple endocrine neoplasia syndrome type 2
MEPSMedical Expenditure Panel Survey
MetSMetabolic syndrome
MIPSMerit-based Incentive Payment System
mITTModified intent-to-treat
MMRMMixed model for repeated measures
MRI-PDFFMagnetic resonance imaging proton density fat fraction
MTCMedullary thyroid carcinoma
MTDMaximum tolerated dose
MVPMIPS Value Pathway
MWPCMeaningful within-person change
NADACNational Average Drug Acquisition Cost
NAFLDNonalcoholic fatty liver disease
NASHNonalcoholic steatohepatitis
NCHSNational Center for Health Statistics
NDANew drug application
NHANESNational Health and Nutrition Examination Survey
NTSNucleus tractus solitarius
NYHANew York Heart Association
OAOsteoarthritis
OAOOverweight and obesity
OMAObesity Medicine Association
OROdds ratio
OSAObstructive sleep apnea
PAFPopulation attributable fraction
PBMPharmacy benefit manager
PCSPhysical component summary
PDPharmacodynamics
PDCProportion of days covered
PKPharmacokinetics
POBy mouth (oral)
QALYQuality-adjusted life year
QDOnce daily
QMOnce monthly
QOWOnce every other week
QWOnce weekly
RCTRandomized controlled trial
REMSRisk Evaluation and Mitigation Strategy
SADSingle ascending dose
SAESerious adverse event
SBPSystolic blood pressure
SCSubcutaneous
SDStandard deviation
SEStandard error
SF-1212-Item Short Form Health Survey
SF-3636-Item Short Form Health Survey
SRCSafety Review Committee
T1/2Elimination half-life
T2DType 2 diabetes
T2DMType 2 diabetes mellitus
TEAETreatment-emergent adverse event
TESAETreatment-emergent serious adverse event
TmaxTime to maximum plasma concentration
TOSThe Obesity Society
TrOOPTrue out-of-pocket
ULNUpper limit of normal
USPSTFU.S. Preventive Services Task Force
WACWholesale acquisition cost
WCWaist circumference
WHOWorld Health Organization
WMMWeight management medication